Eli Lilly announced a collaboration with Nvidia to establish an AI innovation laboratory in the San Francisco Bay Area, deploying up to $1 billion over five years. The facility will unite Eli Lilly’s drug discovery scientists with Nvidia’s AI engineers to develop advanced machine-learning models designed to shorten the timeline for identifying and optimizing novel therapeutic compounds. This effort builds on last year’s supercomputer project and the TuneLab platform, giving the company access to vast clinical trial datasets and reinforcing its commitment to integrating cutting-edge computing power into pharmaceutical research.

The company’s tirzepatide-based weight management therapy became the world’s top-selling drug in the third quarter, driving a 54% year-over-year revenue increase to $17.6 billion and boosting earnings per share to $6.21, a 480% rise compared with the prior year. Analysts project that strong demand for this therapy will sustain robust top-line growth through the end of the decade, underpinning the company’s financial performance and reinforcing its leadership in obesity and metabolic disease treatment.

Beyond its core metabolic franchise, the company is preparing to launch orforglipron, an oral medication targeting diabetes and obesity, and is advancing retatrutide, which has shown promising clinical results. Recent approvals for therapies in eczema (Ebglyss), cancer (Jaypirca), and Alzheimer’s disease (Kisunla) signal progress in oncology, immunology, pain management and rare diseases. This diversified pipeline strategy aims to reduce reliance on a single therapeutic area and to generate multiple growth drivers over the next five years.

Robust free cash flow generation has enabled consistent dividend increases, with the payout rising by 103.5% over the past five years. The company maintains an investment-grade balance sheet and continues to allocate capital toward shareholder returns while funding R&D and strategic initiatives. This combination of cash generation, disciplined capital allocation and dividend growth underlines the company’s appeal to both growth-oriented and income-seeking investors.